A phase II clinical study (NCT03066206) for treating EGFR ex20ins-mutated NSCLC demonstrated that the ORR was 58%, the mPFS was 5.6 months, and the DCR was 90% (80). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.